Sacituzumab Tirumotecan — Drug Intelligence | 23 EU Trials

Filter these 23 trials by condition, phase, country and more.

Open in Search →

23 Registered trials

19 Recruiting

4 Completed trials

1 Sponsors

18 Countries

Phase III

Phase I/II

Phase III: 16 Phase II: 1 Phase I/II: 5 Phase I (FiH): 1

Oversight events:

2 serious breaches 9 temporary halts 6 unexpected events across 8 trials

View oversight register →

Indications tested

Non-small cell lung cancer metastatic 2 Non-small cell lung cancer stage IIIB 1 Bladder cancer 1 Non-small cell lung cancer 1 Non-small cell lung cancer stage IIIA 1 Ovarian epithelial cancer recurrent 1 Hormone receptor positive breast cancer 1 Ovarian cancer recurrent 1 Gastrooesophageal cancer 1 Non-small cell lung cancer stage II 1 Ovarian cancer 1 Ductal adenocarcinoma of pancreas 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 23

All trials

23 total

A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting

2023-508047-40-00 Phase III 15 countries Merck Sharp & Dohme LLC
A clinical study of MK-1084 with other treatments for non-small cell lung cancer (MK-3475-01F) Recruiting

2024-512248-47-00 Phase I/II 6 countries Merck Sharp & Dohme LLC
A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036) Recruiting

2025-521514-26-00 Phase III 13 countries Merck Sharp & Dohme LLC
A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting

2023-508015-23-00 Phase III 14 countries Merck Sharp & Dohme LLC
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Phase III 16 countries Merck Sharp & Dohme LLC
A clinical trial of sacituzumab tirumotecan to treat urothelial cancer (MK-2870-031) Recruiting

2024-520014-22-00 Phase III 8 countries Merck Sharp & Dohme LLC
A clinical study of sac-TMT in people with breast cancer (MK-2870-032) Recruiting

2024-520190-12-00 Phase III 14 countries Merck Sharp & Dohme LLC
A clinical study of sacituzumab tirumotecan and pembrolizumab in people with endometrial cancer (MK-2870-033) Recruiting

2024-519331-42-00 Phase III 16 countries Merck Sharp & Dohme LLC
A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting

2024-516834-36-00 Phase III 13 countries Merck Sharp & Dohme LLC
KEYMAKER U01 Sub-Study E Signal-finding study to test investigational agents with pembrolizumab in combination with chemotherapy in newly di… Recruiting

2023-509234-19-00 Phase II 5 countries Merck Sharp & Dohme LLC
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Phase III 13 countries Merck Sharp & Dohme LLC
Substudy 06D: Combination Therapies in 2L Advanced Gastroesophageal Adenocarcinoma Recruiting

2023-509306-29-00 Phase I/II 4 countries Merck Sharp & Dohme LLC
Substudy 06C: Combination Therapies in Gastroesophageal Adenocarcinoma Recruiting

2023-509307-33-00 Phase I/II 4 countries Merck Sharp & Dohme LLC
Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting

2023-510128-66-00 Phase III 10 countries Merck Sharp & Dohme LLC
A clinical study of MK-2870 alone or with other treatments to treat gastrointestinal cancers (MK-9999-02A) Recruiting

2023-508703-21-00 Phase I/II 2 countries Merck Sharp & Dohme LLC
A clinical study of MK-2870 and chemotherapy to treat lung cancer (MK-2870-009) Recruiting

2023-504910-31-00 Phase III 5 countries Merck Sharp & Dohme LLC
Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting

2023-504962-52-00 Phase III 15 countries Merck Sharp & Dohme LLC
A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting

2023-503376-24-00 Phase III 9 countries Merck Sharp & Dohme LLC
Study of Combination Therapies in Esophageal Cancer Recruiting

2023-505189-26-00 Phase I/II 3 countries Merck Sharp & Dohme LLC
MK-2870 versus Chemotherapy in Previously Treated or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other … Ended

2023-503539-16-00 Phase III 7 countries Merck Sharp & Dohme LLC
A Phase 1/2 Study of MK-2870 plus EV plus Pembrolizumab in la/mUC Ended

2023-506387-14-00 Phase I (FiH) 5 countries Merck Sharp & Dohme LLC
A clinical study of MK-2870 in people with stomach cancer (MK-2870-015) Ended

2023-505423-31-00 Phase III 7 countries Merck Sharp & Dohme LLC
MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended

2023-504816-14-00 Phase III 15 countries Merck Sharp & Dohme LLC

Showing 1–23 of 23 trials

← All drugs A–Z